These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 23261733)

  • 1. Efficacy of combination of fluoxetine and cognitive behavioral therapy and fluoxetine alone for the treatment of obsessive compulsive disorder.
    Giasuddin NA; Nahar JS; Morshed NM; Balhara YP; Sobhan MA
    Pak J Pharm Sci; 2013 Jan; 26(1):95-8. PubMed ID: 23261733
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of cognitive-behaviour therapy for obsessive-compulsive disorder patients non-responding to fluoxetine.
    Kampman M; Keijsers GP; Hoogduin CA; Verbraak MJ
    Acta Psychiatr Scand; 2002 Oct; 106(4):314-9. PubMed ID: 12225499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cognitive-behavioral therapy as an adjunct to serotonin reuptake inhibitors in obsessive-compulsive disorder: an open trial.
    Simpson HB; Gorfinkle KS; Liebowitz MR
    J Clin Psychiatry; 1999 Sep; 60(9):584-90. PubMed ID: 10520976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical predictors of long-term outcome in obsessive-compulsive disorder.
    Jakubovski E; Diniz JB; Valerio C; Fossaluza V; Belotto-Silva C; Gorenstein C; Miguel E; Shavitt RG
    Depress Anxiety; 2013 Aug; 30(8):763-72. PubMed ID: 23109056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential prefrontal gray matter correlates of treatment response to fluoxetine or cognitive-behavioral therapy in obsessive-compulsive disorder.
    Hoexter MQ; Dougherty DD; Shavitt RG; D'Alcante CC; Duran FL; Lopes AC; Diniz JB; Batistuzzo MC; Evans KC; Bressan RA; Busatto GF; Miguel EC
    Eur Neuropsychopharmacol; 2013 Jul; 23(7):569-80. PubMed ID: 22841131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cognitive behavior therapy in medication non-responders with obsessive-compulsive disorder: a prospective 1-year follow-up study.
    Anand N; Sudhir PM; Math SB; Thennarasu K; Janardhan Reddy YC
    J Anxiety Disord; 2011 Oct; 25(7):939-45. PubMed ID: 21689902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fluoxetine in preschool children with obsessive-compulsive disorder.
    Coskun M; Zoroglu S
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):297-300. PubMed ID: 19519265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-month treatment study.
    Bergeron R; Ravindran AV; Chaput Y; Goldner E; Swinson R; van Ameringen MA; Austin C; Hadrava V
    J Clin Psychopharmacol; 2002 Apr; 22(2):148-54. PubMed ID: 11910259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter volumes in obsessive-compulsive disorder before and after fluoxetine or cognitive-behavior therapy: a randomized clinical trial.
    Hoexter MQ; de Souza Duran FL; D'Alcante CC; Dougherty DD; Shavitt RG; Lopes AC; Diniz JB; Deckersbach T; Batistuzzo MC; Bressan RA; Miguel EC; Busatto GF
    Neuropsychopharmacology; 2012 Feb; 37(3):734-45. PubMed ID: 22030709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Group cognitive-behavioral therapy versus selective serotonin reuptake inhibitors for obsessive-compulsive disorder: a practical clinical trial.
    Belotto-Silva C; Diniz JB; Malavazzi DM; Valério C; Fossaluza V; Borcato S; Seixas AA; Morelli D; Miguel EC; Shavitt RG
    J Anxiety Disord; 2012 Jan; 26(1):25-31. PubMed ID: 21907540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB; Foa EB; Liebowitz MR; Huppert JD; Cahill S; Maher MJ; McLean CP; Bender J; Marcus SM; Williams MT; Weaver J; Vermes D; Van Meter PE; Rodriguez CI; Powers M; Pinto A; Imms P; Hahn CG; Campeas R
    JAMA Psychiatry; 2013 Nov; 70(11):1190-9. PubMed ID: 24026523
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of CBT with fluoxetine works better for obsessive-compulsive disorder.
    Giasuddin NA; Nahar JS; Morshed NM; Balhara YP
    Asian J Psychiatr; 2012 Mar; 5(1):113. PubMed ID: 26878959
    [No Abstract]   [Full Text] [Related]  

  • 15. Does gabapentin lead to early symptom improvement in obsessive-compulsive disorder?
    Onder E; Tural U; Gökbakan M
    Eur Arch Psychiatry Clin Neurosci; 2008 Sep; 258(6):319-23. PubMed ID: 18297416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addition of cognitive-behavioral therapy for nonresponders to medication for obsessive-compulsive disorder: a naturalistic study.
    Tundo A; Salvati L; Busto G; Di Spigno D; Falcini R
    J Clin Psychiatry; 2007 Oct; 68(10):1552-6. PubMed ID: 17960971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized clinical trial of cognitive-behavioral group therapy and sertraline in the treatment of obsessive-compulsive disorder.
    Sousa MB; Isolan LR; Oliveira RR; Manfro GG; Cordioli AV
    J Clin Psychiatry; 2006 Jul; 67(7):1133-9. PubMed ID: 16889458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Delayed obsessive-compulsive disorder symptom exacerbation after a single dose of a serotonin antagonist in fluoxetine-treated but not untreated patients.
    Greenberg BD; Benjamin J; Martin JD; Keuler D; Huang SJ; Altemus M; Murphy DL
    Psychopharmacology (Berl); 1998 Dec; 140(4):434-44. PubMed ID: 9888619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Behavioral therapy in children and adolescents with obsessive-compulsive disorder: a pilot study.
    Scahill L; Vitulano LA; Brenner EM; Lynch KA; King RA
    J Child Adolesc Psychopharmacol; 1996; 6(3):191-202. PubMed ID: 9231312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcutaneous electrical acupoint stimulation as an adjunct therapy for obsessive-compulsive disorder: A randomized controlled study.
    Feng B; Zhang ZJ; Zhu RM; Yuan GZ; Luo LY; McAlonan GM; Xu FZ; Chen J; Liu LY; Lv YY; Wong HK; Zhang Y; Zhu LX
    J Psychiatr Res; 2016 Sep; 80():30-37. PubMed ID: 27281260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.